ANTI-FLT3 ANTIBODIES, CARS, CAR T CELLS AND METHODS OF USE
Provided herein are anti-FLT3 antibodies or antigen binding fragments thereof, including heavy chain variable region, light chain variable region and single chain fragments (such as humanized anti-FLT3 antibodies and fragments thereof). In some aspects, the antibodies or fragments specifically bind...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
23.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided herein are anti-FLT3 antibodies or antigen binding fragments thereof, including heavy chain variable region, light chain variable region and single chain fragments (such as humanized anti-FLT3 antibodies and fragments thereof). In some aspects, the antibodies or fragments specifically bind human FLT3. Also provided herein are recombinant receptors, such as chimeric antigen receptors (CARs), comprising such antibodies or fragments. Also provided herein are immune cells comprising such CARs, such as CAR T cells. Also provided herein are methods of use of such antibodies or fragments, CARs and immune cells.
L'invention concerne des anticorps anti-FLT3 ou des fragments de liaison à l'antigène de ceux-ci, comprenant une région variable de chaîne lourde, une région variable de chaîne légère et des fragments à chaîne unique (tels que des anticorps anti-FLT3 humanisés et des fragments de ceux-ci). Dans certains aspects, les anticorps ou fragments se lient de manière spécifique à FLT3 humain. L'invention concerne également des récepteurs recombinants, tels que des récepteurs antigéniques chimériques (CAR), comprenant de tels anticorps ou fragments. L'invention concerne également des cellules immunitaires comprenant ces CAR, tels que des cellules CAR-T. L'invention concerne en outre des procédés d'utilisation de ces anticorps ou fragments, CAR et cellules immunitaires. |
---|---|
Bibliography: | Application Number: CA20223229526 |